Search Within

William Thomas Johnson

  1. "Human Oncology and Pathogenesis Program"
Formats
  1. Meeting Abstract (17)
  2. Journal Article (6)
  3. Research Letter (2)
Groups
  1. Center for Hematologic Malignancies (25)
  2. Department of Medicine (25)
  3. GSK Faculty (25)
  4. Hematologic Malignancies, Division of (25)
  5. Human Oncology and Pathogenesis Program (25)
  6. Lymphoma (25)

More Groups

People
  1. Alison Moskowitz (24)
  2. Santosha Vardhana (24)
  3. Steven Horwitz (24)
  4. Gilles Salles (23)
  5. Ariela Noy (22)
  6. Lorenzo Falchi (22)

More People

Years
  1. 2025 (2)
  2. 2024 (5)
  3. 2023 (12)
  4. 2022 (4)
  5. 2021 (2)
Publications
  1. Blood (15)
  2. Blood Advances (3)
  3. Haematologica (2)
  4. Hematological Oncology (2)
  5. Journal of Clinical Oncology (2)
  6. Blood Cancer Journal (1)
Publishers
  1. American Society of Hematology (18)
  2. American Society of Clinical Oncology (2)
  3. Ferrata Storti Foundation (2)
  4. Wiley Blackwell (2)
  5. Nature Publishing Group (1)

Results (25)

Export to EndNote / Excel | PubMed

Citation style sort is year ascending, and then by author or title. Author ascending is default.
  • Molecular profiling across lymphoma subtypes using MSK-impact next generation sequencing
    Meeting Abstract

    Batlevi, C. L.; Drill, E.; Okwali, M.; Ptashkin, R.; Caron, P. C.; Epstein-Peterson, Z. D.; Falchi, L.; Hamilton, A.; Hamlin, P. A.; Horwitz, S. M.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Immune signature of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Meeting Abstract

    Wills, B.; Ganesan, N.; Shah, G. L.; Wong, P.; Argyropoulos, K. V.; Sen, F.; Dogan, A.; Straus, D. J.; Noy, A.; Kumar, A.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Emapalumab for malignancy-associated hemophagocytic lymphohistiocytosis: The Memorial Sloan Kettering Cancer Center experience
    Meeting Abstract

    Johnson, W. T.; Epstein-Peterson, Z. D.; Ganesan, N.; Chang, T.; Galasso, N.; Stuver, R.; Khan, N.; Salles, G.; Moskowitz, A. J.; Vardhana, S.; more...
    Blood (2022)

    Fulltext@MSK | Save
  • Interim efficacy analysis of a phase II study demonstrates promising activity of the combination of pembrolizumab (PEM) and entinostat (ENT) in relapsed and refractory (R/R) Hodgkin lymphoma (HL)
    Meeting Abstract

    Sermer, D. J.; Vardhana, S.; Biggar, E.; Moskowitz, A. J.; Joffe, E.; Khan, N.; Straus, D. J.; Kumar, A.; Zelenetz, A. D.; Horwitz, S. M.; more...
    Blood (2021)

    Fulltext@MSK | Save
  • Phase II trial of pembrolizumab plus gemcitabine, vinorelbine, and liposomal doxorubicin as second-line therapy for relapsed or refractory classical Hodgkin lymphoma
    Journal Article

    Moskowitz, A. J.; Shah, G.; Schòˆder, H.; Ganesan, N.; Drill, E.; Hancock, H.; Davey, T.; Perez, L.; Ryu, S.; Sohail, S.; more...
    Journal of Clinical Oncology (2021)

    Fulltext@MSK | Save